G. Bruera, E. Ricevuto, G. Masi, F. Loupakis, and L. Salvatore, Intensive chemotherapy of metastatic colorectal cancer: weighing between safety and clinical efficacy Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial, Evaluation of Lancet Oncol Exp Opin Biol Ther, vol.11, issue.11, pp.845-52821, 2010.

G. Masi, E. Vasile, F. Loupakis, S. Cupini, L. Fornaro et al., Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis, JNCI Journal of the National Cancer Institute, vol.103, issue.1, pp.21-30, 2011.
DOI : 10.1093/jnci/djq456

G. Masi, F. Loupakis, L. Salvatore, L. Fornaro, C. Cremolini et al., Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial, The Lancet Oncology, vol.11, issue.9, pp.845-852, 2010.
DOI : 10.1016/S1470-2045(10)70175-3

G. Bruera, A. Santomaggio, K. Cannita, L. Baldi, P. Tudini et al., "Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study, BMC Cancer, vol.28, issue.13, p.67, 2010.
DOI : 10.1016/S0140-6736(00)02528-9

C. Garufi, A. Torsello, S. Tumolo, G. Ettorre, M. Zeuli et al., Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadiuvant chemotherapy in colorectal liver metastases

G. Bruera, K. Cannita, F. Giuliante, L. Baldi, P. Vicentini et al., Effectiveness of Liver Metastasectomies in Patients With Metastatic Colorectal Cancer Treated With FIr-B/FOx Triplet Chemotherapy Plus Bevacizumab, Clinical Colorectal Cancer, vol.11, issue.2, pp.119-126, 2012.
DOI : 10.1016/j.clcc.2011.11.002

Y. Yarden and M. Sliwkowsky, Untangling the ErbB signalling network, Nature Reviews Molecular Cell Biology, vol.2, issue.2, pp.127-137, 2001.
DOI : 10.1038/35052073

M. Scaltriti and J. Baselga, The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy, Clinical Cancer Research, vol.12, issue.18, pp.5268-5272, 2006.
DOI : 10.1158/1078-0432.CCR-05-1554

J. Mccubrey, L. Steelman, S. Abrams, J. Lee, F. Chang et al., Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance, Advances in Enzyme Regulation, vol.46, issue.1, pp.249-279, 2006.
DOI : 10.1016/j.advenzreg.2006.01.004

S. Forbes, J. Clements, E. Dawson, S. Bamford, T. Webb et al., COSMIC 2005, British Journal of Cancer, vol.57, issue.2, pp.318-322, 2005.
DOI : 10.1126/science.1096096
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361125

H. Andreyev, A. Norman, D. Cunningham, J. Oates, B. Dix et al., Kirsten ras mutations in patients with colorectal cancer: the ???RASCAL II??? study, British Journal of Cancer, vol.319, issue.5, pp.692-696, 2001.
DOI : 10.1054/bjoc.2001.1964

N. Normanno, S. Tejpar, F. Morbillo, D. Luca, A. Van-cutsem et al., Implications for KRAS status and EGFR-targeted therapies in metastatic CRC, Nature Reviews Clinical Oncology, vol.276, issue.9, pp.519-527, 2009.
DOI : 10.1038/nrclinonc.2009.111

S. Schubbert, K. Shannon, and G. Bollag, Hyperactive Ras in developmental disorders and cancer, Nature Reviews Cancer, vol.91, issue.4, pp.295-308, 2007.
DOI : 10.1038/nrc2109

W. De-roock, B. Claes, D. Bernasconi, D. Schutter, J. Biesmans et al., Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis, The Lancet Oncology, vol.11, issue.8, pp.753-762, 2010.
DOI : 10.1016/S1470-2045(10)70130-3

P. Zauber, M. Sabbath-solitare, S. Marotta, and D. Bishop, Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas, Molecular Pathology, vol.56, issue.>3, pp.137-140, 2003.
DOI : 10.1136/mp.56.3.137

S. Artale, A. Sartore-bianchi, S. Veronese, V. Gambi, C. Sarnataro et al., in Primary and Matched Metastatic Sites of Colorectal Cancer, Journal of Clinical Oncology, vol.26, issue.25, pp.4217-4219, 2008.
DOI : 10.1200/JCO.2008.18.7286

M. Etienne-grimaldi, J. Formento, M. Francoual, E. Francois, P. Formento et al., K-Ras Mutations and Treatment Outcome in Colorectal Cancer Patients Receiving Exclusive Fluoropyrimidine Therapy, Clinical Cancer Research, vol.14, issue.15, pp.4830-4835, 2008.
DOI : 10.1158/1078-0432.CCR-07-4906

I. Albanese, A. Scibetta, M. Migliavacca, A. Russo, V. Bazan et al., Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations, Biochemical and Biophysical Research Communications, vol.325, issue.3, pp.784-791, 2004.
DOI : 10.1016/j.bbrc.2004.10.111

J. Oudejans, R. Slebos, F. Zoetmulder, and W. Mooi, Differential activation ofras genes by point mutation in human colon cancer with metastases to either lung or liver, International Journal of Cancer, vol.319, issue.6, pp.875-879, 1991.
DOI : 10.1002/ijc.2910490613

H. Hurwitz, Y. J. Ince, W. Novotny, W. Rosen, and O. , The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-ras Mutation Status: Analysis of a Phase III Study of Bevacizumab with Chemotherapy in Previously Untreated Metastatic Colorectal Cancer, The Oncologist, vol.14, issue.1, pp.22-28, 2009.
DOI : 10.1634/theoncologist.2008-0213

E. Van-cutsem, C. Kohne, E. Hitre, J. Zaluski, C. Chien et al., Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer, New England Journal of Medicine, vol.360, issue.14, pp.1408-1417, 2009.
DOI : 10.1056/NEJMoa0805019

C. Bokemeyer, I. Bondarenko, A. Makhson, J. Hartmann, J. Aparicio et al., Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.27, issue.5, pp.663-671, 2009.
DOI : 10.1200/JCO.2008.20.8397

C. Ficorella, E. Ricevuto, M. Morelli, R. Morese, K. Cannita et al., Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study, Oncology Reports, vol.15, pp.1345-1350, 2006.
DOI : 10.3892/or.15.5.1345

M. Morelli, A. Santomaggio, E. Ricevuto, K. Cannita, D. Galitiis et al., on behalf of CINBO (Consorzio Interuniversitario Nazionale per la Bio- Oncologia): Triplet schedule of weekly 5-Fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study, Oncol Rep, vol.23, pp.1635-1675, 2010.

D. Fiore, F. Blanchard, F. Charbonnier, F. , L. Pessot et al., Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy, British Journal of Cancer, vol.14, issue.8, pp.1166-1169, 2007.
DOI : 10.1093/jnci/92.3.205

A. Lamy, F. Blanchard, L. Pessot, F. Sesboué, R. et al., Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls, Modern Pathology, vol.46, issue.8, pp.1090-1100, 2011.
DOI : 10.1038/modpathol.2011.60

P. Therasse, S. Arbuck, E. Eisenhauer, J. Wanders, R. Kaplan et al., New Guidelines to Evaluate the Response to Treatment in Solid Tumors, JNCI: Journal of the National Cancer Institute, vol.92, issue.3, pp.205-216, 2000.
DOI : 10.1093/jnci/92.3.205

E. Kaplan and P. Meier, Nonparametric Estimation from Incomplete Observations, Journal of the American Statistical Association, vol.37, issue.282, pp.457-481, 1958.
DOI : 10.1214/aoms/1177731566

R. Peto and J. Peto, Asymptotically Efficient Rank Invariant Test Procedures, Journal of the Royal Statistical Society. Series A (General), vol.135, issue.2, pp.185-206, 1972.
DOI : 10.2307/2344317

J. Hecht, E. Mitchell, T. Chidiac, C. Hagenstad, C. Spigel et al., A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.27, issue.5, pp.672-680, 2009.
DOI : 10.1200/JCO.2008.19.8135

J. Tol, M. Koopman, A. Cats, C. Rodenburg, G. Creemers et al., Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer, Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer, pp.563-572, 2009.
DOI : 10.1056/NEJMoa0808268

J. Douillard, S. Siena, J. Cassidy, J. Tabernero, R. Burkes et al., Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study, Journal of Clinical Oncology, vol.28, issue.31, pp.4697-4705, 2010.
DOI : 10.1200/JCO.2009.27.4860

C. Bokemeyer, I. Bondarenko, J. Hartmann, F. De-braud, G. Schuch et al., Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study, Annals of Oncology, vol.22, issue.7, pp.1535-1546, 2011.
DOI : 10.1093/annonc/mdq632

W. Ince, A. Jubb, S. Holden, E. Holmgren, P. Tobin et al., Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab, JNCI Journal of the National Cancer Institute, vol.97, issue.13, pp.981-989, 2005.
DOI : 10.1093/jnci/dji174

G. Folprecht, T. Gruenberger, W. Bechstein, H. Raab, F. Lordick et al., Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial, The Lancet Oncology, vol.11, issue.1, pp.38-47, 2010.
DOI : 10.1016/S1470-2045(09)70330-4

S. Guerrero, I. Casanova, L. Farrè, A. Mazo, G. Capellà et al., K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression, Cancer Res, vol.60, pp.6750-6756, 2000.

. Bruera, Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease, BMC Medicine, vol.60, issue.1, p.135, 2012.
DOI : 10.1016/S1470-2045(09)70330-4
URL : https://hal.archives-ouvertes.fr/inserm-00764322